Recommendations for the clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia (VITT) for SARS-CoV-2 infections: Communication from the ISTH SSC Subcommittee on Platelet Immunology

Abstract Vaccine campaigns are currently underway worldwide to combat the COVID-19 pandemic The newly developed vaccines are highly effective with minimal adverse effects Recently, the AstraZeneca vaccine has raised public alarm with concerns regarding the rare, but serious, development of thrombotic events, now known as vaccine-induced immune thrombotic thrombocytopenia (VITT) These thrombotic events appear similar to heparin-induced thrombocytopenia (HIT), both clinically and pathologically In this manuscript, the ISTH SSC Subcommittee on Platelet Immunology outlines guidelines on how to recognize, diagnose and manage patients with VITT